ClinicalTrials.Veeva

Menu

Anticoagulation Alone Versus Anticoagulation and Aspirin Following Transcatheter Aortic Valve Interventions (1:1) (AVATAR)

C

Centre Hospitalier Universitaire de Nīmes

Status and phase

Completed
Phase 4

Conditions

Transcatheter Aortic Valve Replacement

Treatments

Drug: Vitamin K antagonist or direct oral anticoagulant treatment
Drug: Aspirin

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT02735902
LOCAL/2016/GC-01
2016-000352-98 (EudraCT Number)

Details and patient eligibility

About

The main objective of this study is to demonstrate that a single anticoagulant therapy is superior to a combination of anticoagulant and antiplatelet therapy on the net clinical benefit estimated at 12 months after a Transcatheter Aortic Valve Intervention (TAVI) according to BARC2 criteria (bleeding complications; Mehran et al 2011) and VARC 3 (other complications; Kappetein et al 2012)..

Full description

The secondary objectives of this study are to evaluate the following at 3 months, 6 months and 12 months after TAVI in both groups:

  1. Mortality (all causes).
  2. Cardiovascular mortality.
  3. The occurrence of myocardial infarction.
  4. The occurrence of stroke.
  5. The occurrence of valve thrombosis.
  6. The occurrence of major bleeding (BARC ≥ 3).
  7. The occurrence of minor bleeding (2 ≤ BARC <3).
  8. Treatment compliance.

Enrollment

170 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • The patient or his/her representative must have given free and informed consent and signed the consent
  • The patient must be insured or beneficiary of a health insurance plan
  • The patient is available for 12 months of follow-up
  • The patient underwent a successful transcutaneous implant procedure for an aortic valve
  • The patient required anticoagulant treatment (AVK or DOAC) excepted rivaroxaban the day of inclusion
  • The patient is stable on anticoagulant treatment

Exclusion criteria

  • The patient is participating in another study
  • The patient is in an exclusion period determined by a previous study
  • The patient or his/her representative refuses to sign the consent
  • It is impossible to correctly inform the patient or his/her representative
  • The patient is pregnant or breastfeeding
  • The patient has a contraindication (or an incompatible drug association) for a treatment used in this study
  • The patient had a coronary stent for less than 12 months
  • The patient does not require treatment with aspirin or any other antiplatelet agent
  • The patient has a history of aspirin allergy
  • High bleeding risk; such as platelets <50,000 / mm3 during screening, Hb <8.5 g / dL, history of intracranial hemorrhage or subdural hematoma, major surgery, parenchymal organ biopsy or severe trauma within 30 days before inclusion, active gastrointestinal ulcer in the last 3 months;
  • History of Stroke in the last 3 months;
  • Moderate or severe liver affection associated with coagulopathy
  • Active infectious endocarditis
  • Active tumor treated at the time of inclusion associated with expected survival less than one year
  • Not following countraindications specific to the molecules used fo the patients receiving DOAC

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

170 participants in 2 patient groups

vitamin K antagonist or Direct oral anticoagulant treatment
Experimental group
Description:
In this group, patients will receive monotherapy via anticoagulant (AVK or DOAC) excepted rivaroxaban; this treatment given corresponds to the anticoagulant treatment the patient was receiving before surgery. A data collection book for monitoring INR values and dates for the next 12 months is given to the patient. Intervention: anticoagulant
Treatment:
Drug: Vitamin K antagonist or direct oral anticoagulant treatment
vitamin K antagonist or Direct oral anticoagulant + Aspirin
Active Comparator group
Description:
In this group, patients will receive combination therapy via anticoagulant (AVK or DOAC) and aspirin, whose daily dose is between 75 mg and 100 mg; the anticoagulant treatment administered corresponds to the anticoagulant treatment the patient was receiving before the procedure, monitored and adapted according to current recommendations. A data collection book for monitoring INR values and dates for the next 12 months is given to the patient. Intervention: anticoagulant Intervention: Aspirin
Treatment:
Drug: Aspirin
Drug: Vitamin K antagonist or direct oral anticoagulant treatment

Trial contacts and locations

6

Loading...

Central trial contact

Carey Suehs, PhD; Guillaume Cayla, MD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems